Zobrazeno 81 - 84
of 84
pro vyhledávání: '"329"'
Autor:
Lisa Rybicki, Brian J. Bolwell, Ronald Sobecks, Elizabeth Kuczkowski, Stacey Brown, Steven Andresen, Matt Kalaycio, Brad Pohlman
Publikováno v:
Blood. 106:1764-1764
Many high-dose chemotherapy preparative regimens include agents known to cause pulmonary toxicity such as BCNU. Chemotherapy induced pulmonary toxicity may be fatal. From 1/1/93 to 12/31/04 we treated 533 NHL patients with oral busulfan 14mg/kg, VP-1
Autor:
James R. Berenson, Robert Vescio, Sonia Gauron, Horst Schran, Regina A. Swift, Jannick Denouel, Pierre Major, Christina Rivera, Sanela Bilic
Publikováno v:
Blood. 106:5192-5192
BACKGROUND: Zoledronic acid has demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma. However, bisphosphonates are known to have dose-dependent and infusion rate-dependent effects on renal function and p
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli
Publikováno v:
Blood. 104:4939-4939
Background: Zoledronic acid is a new-generation bisphosphonate with demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma and solid tumors using a monthly regimen of 4 mg infused over 15 minutes. This pha